Clinical Trials Logo

Metastatic Merkel Cell Carcinoma clinical trials

View clinical trials related to Metastatic Merkel Cell Carcinoma.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT03816332 Active, not recruiting - Metastatic Melanoma Clinical Trials

Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers

Start date: November 8, 2019
Phase: Phase 1
Study type: Interventional

This phase I trial studies how well tacrolimus, nivolumab, and ipilimumab work in treating kidney transplant recipients with cancer that cannot be removed by surgery (unresectable) or has spread to other places in the body (metastatic). Tacrolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving tacrolimus, nivolumab, and ipilimumab may work better in treating kidney transplant recipients with cancer compared to chemotherapy, surgery, radiation therapy, or targeted therapies.

NCT ID: NCT03599713 Active, not recruiting - Clinical trials for Metastatic Merkel Cell Carcinoma

A Study of INCMGA00012 in Metastatic Merkel Cell Carcinoma (POD1UM-201)

Start date: February 25, 2019
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the clinical activity and safety of INCMGA00012 in participants with advanced/metastatic Merkel cell carcinoma (MCC).

NCT ID: NCT03304639 Active, not recruiting - Clinical trials for Metastatic Merkel Cell Carcinoma

Testing the Addition of Radiation Therapy to Immunotherapy for Merkel Cell Carcinoma

Start date: June 12, 2018
Phase: Phase 2
Study type: Interventional

This randomized phase II trial studies how well pembrolizumab with or without stereotactic body radiation therapy works in treating patients with Merkel cell cancer that has spread to other places in the body (advanced). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Stereotactic body radiation therapy uses special equipment to position a patient and deliver radiation to tumors with high precision. This method can kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue. Giving pembrolizumab with stereotactic body radiation therapy may work better in treating patients with Merkel cell cancer.